A detailed history of Vanguard Group Inc transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 24,915,300 shares of IOVA stock, worth $200 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
24,915,300
Previous 22,812,820 9.22%
Holding current value
$200 Million
Previous $185 Million 99.09%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$7.59 - $17.47 $16 Million - $36.7 Million
2,102,480 Added 9.22%
24,915,300 $369 Million
Q4 2023

Feb 14, 2024

BUY
$3.3 - $8.89 $2.21 Million - $5.95 Million
669,350 Added 3.02%
22,812,820 $185 Million
Q3 2023

Nov 14, 2023

BUY
$4.44 - $8.79 $7.76 Million - $15.4 Million
1,748,082 Added 8.57%
22,143,470 $101 Million
Q2 2023

Aug 14, 2023

BUY
$5.36 - $9.06 $36.7 Million - $62.1 Million
6,855,259 Added 50.63%
20,395,388 $144 Million
Q1 2023

May 15, 2023

SELL
$5.53 - $8.22 $5.1 Million - $7.59 Million
-922,953 Reduced 6.38%
13,540,129 $82.7 Million
Q4 2022

Feb 10, 2023

BUY
$5.62 - $10.0 $1.18 Million - $2.09 Million
209,328 Added 1.47%
14,463,082 $92.4 Million
Q3 2022

Nov 14, 2022

BUY
$9.53 - $13.11 $8.49 Million - $11.7 Million
890,727 Added 6.67%
14,253,754 $137 Million
Q2 2022

Aug 12, 2022

BUY
$6.38 - $18.33 $6.52 Million - $18.7 Million
1,021,374 Added 8.28%
13,363,027 $148 Million
Q1 2022

May 13, 2022

BUY
$12.38 - $19.1 $1.78 Million - $2.75 Million
143,866 Added 1.18%
12,341,653 $205 Million
Q4 2021

Feb 14, 2022

BUY
$16.55 - $27.63 $4.45 Million - $7.43 Million
268,798 Added 2.25%
12,197,787 $233 Million
Q3 2021

Nov 12, 2021

SELL
$20.35 - $26.63 $6.26 Million - $8.19 Million
-307,422 Reduced 2.51%
11,928,989 $294 Million
Q2 2021

Aug 13, 2021

BUY
$16.33 - $33.07 $200 Million - $405 Million
12,236,411 New
12,236,411 $318 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.27B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.